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  Implication for health policy/practice/research/medical 
education:
Autoimmune hepatitis is a quite serious disease, and will get worse 
if not treated properly. AIH is a disease that needs to be managed 
under the supervision of a team of specialists, including at least 
one hepatologist or a gastroenterologist with an interest in liver 
disease, as well as a laboratory that can measure all serum autoan-
tibodies with accurate titres. This article is highly recommended 
to hepatologists, gastroenterologists, virologists, general practitio-
ners, and researchers who are interested in public health.
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Autoimmune hepatitis (AIH) has been the subject of 
numerous studies, from the late 1940s when it ﬁrst came 
to clinical attention, and various aspects of this disease 
have been analyzed throughout the world (1). Although 
its clinical, laboratory and histological features, as well 
as demographical characteristics, have been extensive-
ly studied in many countries and in diﬀerent ethnic 
groups, there have been no such statistics or analysis 
available for Iranian patients with AIH until now. The 
number of Iranian studies published so far about auto-
immune hepatitis has been very limited. We only have 
two studies concerning the clinical characteristics of 
Iranian adult patients with AIH (2, 3) and the informa-
tion obtained can be summarized as follows: Iranian 
patients with AIH are typically women (male/female: 1:4), 
usually in their 30s and almost all of them have type 1 of 
the disease. We also have other Iranian studies regarding 
coeliac disease in patients with AIH (4, 5), studies about 
cyclosporine therapy for AIH (6, 7), surveys on the impact 
of immunosuppressive treatment on cirrhosis and liver 
ﬁbrosis in AIH (8, 9) and ﬁnally, some scattered studies 
related to the role of viruses and gene polymorphisms in 
AIH disease etiology (10-13). However, there has not been 
any rigorous research conducted so far on the long-term 
outcomes of AIH in Iranian patients. In this issue of Hepa-
titis Monthly, Malekzadeh et al. analyzes both the clinical 
features and long term treatment outcomes of 102 Ira-
nian patients diagnosed with AIH (14). This article is both 
the ﬁrst and the largest study detailing clinical aspects 
of AIH and long term outcomes based on data gathered 
from Iranian patients. According to the ﬁndings of this 
study, Iranian patients with AIH have several character-
istics that are similar to other reported AIH series, these 
include; two age-peaks at presentation, clinical biochem-
ical and histopathological features when AIH is ﬁrst diag-
nosed, concurrent autoimmune diseases, and response 
rates to corticosteroids. We also now know that Iranian 
patients with AIH have an excellent 10-year survival rate 74
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of 96%, which is consistent with ﬁndings from previous 
studies carried out on other ethnic groups. 
AIH is a rare disease and there are only a few credible 
data sources on the epidemiological aspects of the dis-
ease. For example, we know that the incidence of AIH 
in New-Zealand is 2 cases per 100,000 persons and its 
point prevalence is 24.5 cases per 100,000 persons (15). 
The point prevalence of AIH in Alaska and Norway is 43 
and 16.9 cases per 100,000 persons, respectively (16, 17). 
However, we don’t have any similar data about the inci-
dence or the prevalence of AIH among Iranians and thus 
it is impossible to compare Iranian data with other coun-
tries. Nevertheless, despite the fact that AIH accounts for 
only 2.6% of liver transplantation in the European Liver 
Transplant Registry (18) and 5.9% of liver transplantation 
in the National Institute of Health Liver Transplantation 
Database (19), a report by Saberiﬁroozi et al. showed that 
of the 480 patients who were over 14 years old and on the 
liver transplantation list from 1994 to 2004 in the Shiraz 
Center for Liver Transplantation, 64 cases (13%) were di-
agnosed with AIH (20) which is a much higher rate than 
what has been seen in the US and European countries. 
In 1993, the International Autoimmune Hepatitis Group 
(IAIHG) codiﬁed diagnostic criteria for AIH and suggest-
ed a scoring system for its diagnosis (21). These criteria 
were later revised by an expanded panel in 1999 (22). The 
scoring system suggested by the IAIHG lists all the dif-
ferent presentations of this disease and the sum of the 
scores determines the accuracy of the diagnosis before 
and after treatment with glucocorticoids. Apart from the 
human leukocyte antigen (HLA) typing test and tests for 
detecting investigational autoantibodies including; the 
asialoglycoprotein receptor (ASGPR), anti actin, anti LC1 
and anti SLA/LP, other tests related to the IAIHG scoring 
system are routinely available in Iranian laboratories. 
Although most of the studies on AIH carried out in Iran 
claim to use the IAIHG scoring system, in order to diag-
nose and categorize patients into deﬁnite and probable 
groups, none of them have any reports on HLA typing or 
frequency of investigational autoantibodies at presenta-
tion (2, 4, 23). Another problem in Iran is the incorrect 
use of other diagnostic tests related to AIH. Common 
mistakes are the evaluation of positive/negative results 
without consulting the titration of serum autoantibody 
levels (ALKM-1, ASMA, ANA and AMA) and the incorrect in-
terpretations of these tests. 
According to the latest guidelines; titres equal to or 
more than 1:40 for all the autoantibodies in adults, and 
in children titres equal to or more than 1:20 for ANA and 
ASMA and the titres equal to or more than 1:10 for ALKM-1, 
are considered to be positive and have scoring values (24, 
25). However, many Iranian medical centers only consid-
er the test positive if the titres are equal to or more than 
1:80. 
Despite the fact that almost all of the credible refer-
ences and guidelines recommend a liver biopsy, before 
the start of treatment for patients who are suspected to 
have AIH (24, 25), we still see in Iran, patients that didn’t 
have any contra-indication to undergoing liver biopsy 
but treated without it.
 Consequently this leads to improper treatment of pa-
tients with glucocorticoids. For example up to 20% of pa-
tients with proven fatty liver disease based on their liver 
histology, had the criteria for a deﬁnite or probable diag-
nosis of AIH before undergoing a liver biopsy (26). Fur-
thermore, according to the revised criteria for AIH (22), 
the necessity for the disease to be present for six months 
to establish its chronicity has been deleted, nevertheless, 
some Iranian physicians still do not start treatment be-
fore establishing chronicity. 
The eﬃcacy of long-term monotherapy with a high 
dose of prednisone (USA), or prednisolone (European 
countries and also Iran), or in lower doses and in com-
bination with azathioprine, was proven to be eﬀective 
in the 1960s and since then this has been the standard 
treatment for AIH (27). A common mistake in therapy of 
AIH among Iranian physicians is starting the treatment 
with non-eﬃcient doses of glucocorticoids. In most ref-
erences it has been emphasized that treatment should 
start with the maximum recommended dose of prednis-
olone (30 mg/day) in combination with 1-2 mg/kg/day of 
azathioprine (24, 25), as doses less than this may lead to a 
delay in achieving remission and consequently postpone 
the achievement of treatment endpoint criteria. 
Other issues which should be taken into consideration 
are the absolute and relative indications for treatment 
(24). It is also very important to ensure that there are no 
contraindications for treatment such as; severe cytope-
nia, morbid obesity or severe osteoporosis (24). Up until 
the present time, there have been many debates on the 
necessity of treatment for patients with relative indica-
tions for treatment. Nevertheless, in recent years these 
discussions have tended to emphasize the importance 
of treatment of asymptomatic patients or patients with 
a mild disease (28). In earlier studies in the Mayo Clinic 
and numerous latter studies, biochemical remission of 
AIH had been deﬁned as a decrease in AST serum levels to 
less than half of normal. Up to 80% of patients can achieve 
these criteria with prednisolone-based treatments (29). 
This issue could have been confusing before, as IAIHG 
had used two diﬀerent terms for remission: one was a de-
crease in AST serum levels to less than half of the upper 
normal limit and the other was full normalization of AST 
(25). Indeed, this issue has now been resolved and almost 
all of the current credible guidelines state that complete 
normalization of serum transaminases must be the ﬁnal 
treatment goal (24). The importance of this issue is that 
even mild, but consistent elevations in serum transami-
nases, can be associated with; persistent hepatitis (30), 
relapse after treatment withdrawal (31), progression to 
cirrhosis (32), and poor prognosis (33). Therefore a treat-
ment endpoint which was considered to be a decrease in 
AST serum levels to less than half of normal, should be 
changed to full normalization (25). 
There are still many important questions to be raised 
concerning practice details in current standard treat-75
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ments. Besides these, other new and promising treat-
ments are awaiting oﬃcial comparisons with current 
standard regimes. Cyclosporine is one of the drugs which 
has proved its eﬃcacy and safety in the treatment of AIH 
in many studies (34, 35) including a survey by Malekza-
deh et al. from Iran (7). Unfortunately, there have been no 
reports on other alternative treatments for AIH in Iran. 
Among other new possible treatments are; budesonide 
and mycophenolate mofetil, the eﬃcacy of the former 
has been recently proved in a big multicentral cohort 
study (36), and the later seems to be a good alternative 
for azathioprine (37). Ursodeoxycholic acid which is usu-
ally used as an adjuvant therapy in the treatment of AIH 
in Iran, is only eﬃcient for AIH patients with concurrent 
overlap syndromes such as primary biliary cirrhosis 
(PBC) and primary sclerosing cholangitis (PSC), but its ef-
ﬁcacy has not been proven in pure AIH cases (38). 
Other alternative strategies in cases of treatment fail-
ure are the administration of; tacrolimus, methotrex-
ate, cyclophosfamide and biologic treatments such as; 
etanercept, rituximab and inﬂiximab (38). There have 
only been a few cases of using each of these strategies 
and in most cases the result were encouraging, but not 
reassuring enough to reach a consequence. At the end, 
it should be emphasized that AIH is a disease that needs 
to be managed under the supervision of a team of spe-
cialists, including at least one hepatologist or a gastro-
enterologist with an interest in liver disease, a specialist 
liver histopathologist, as well as a laboratory that can 
measure all serum autoantibodies with accurate titres. 
Regular meetings held to discuss complicated cases are 
also very helpful and can prevent physicians from mis-
management.
In conclusion, it seems that we are just beginning to un-
derstand the condition of AIH in Iran, as the number of 
studies that have been conducted on AIH in Iran scarcely 
exceeds the number of ﬁngers on both hands. This is-
sue indicates the importance of designing multiple new 
studies on diﬀerent aspects of AIH in Iran. Clinical, labo-
ratory and histological features of Iranian patients with 
AIH have still not been properly identiﬁed, so the ﬁrst 
step required is that new studies must focus on these un-
known aspects of the disease and especially on the diﬀer-
ences among Iranian patients and other ethnic groups. 
Collaboration of major herpetology research centers in 
Iran in a big multicenter cohort study would be a cru-
cially important combined project; this would enable 
an accurate estimation of the epidemiological character-
istics of AIH in Iran and also the long-term outcomes of 
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